ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / XERS
SLS (38) SRPT (27) BRVE (46) TRVI (30) ⌘ Pro Terminal →

Xeris Biopharma Holdings Inc. (XERS) — RQD Stock Rating Cockpit

$10.17 -5.04% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.06

Xeris Biopharma Holdings Inc. (XERS) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $1.95B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on XERS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is XERS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Xeris Biopharma Holdings Inc. (NASDAQ: XERS) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $10.17 (-5.04% 1D, market cap $1.95B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, XERS ranks #127 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does XERS compare to SLS and SRPT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XERS carries a Roarable C (64/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 16.0%. By comparison, SLS (SELLAS Life Sciences Group Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -21.8%, cap $1.95B) and SRPT (Sarepta Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $1.97B). Among the 5-stock peer group, XERS leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for XERS?
▼

Per XERS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001867096), Xeris Biopharma Holdings Inc. generated $291.8M in revenue (+43.7% YoY), $554.0K in net income, and $28.6M in free cash flow against $383.5M in total assets and $220.3M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $10.06 (-1.10%)🧬 Disciplined Float (+0.24% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 9.8% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY • 55.2% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510064
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw B · Rk D+
Cash (16)Whales (16)SEC (12)Macro (9)CEO (11)
Each axis scored 0–20
12M PRICE TARGET CONE+2.7% Base Target
$12 Bull$10 Base$8 Bear
📬 FREE XERS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XERS)Realized 20D OHLCV Swing Band: ±8.7%
Deterministic 5-Pillar Attribution (64/100 Composite)
🔍 WHY XERS SCORES 64/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 9.8% FCF Margin ($28.6M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+16/20 pts (25% of score)

20D Institutional Volume Accumulation (±8.7% realized swing band)

▼ #1 Drag / Risk Factor: Macro Regime Fit9/20 pts (-11 pt drag)

Macro rate sensitivity & RSI-14 (59.7) create a -11 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
72
Grade B$10.20+9.1% Next Q
Q2 (-2Q)
69
Grade B-$11.13-6.1% Next Q
Q3 (-1Q)
67
Grade B-$10.45-2.7% Next Q
Current
64
Grade C$10.17+1.1% Hist 90D α
Trajectory: B (72) → C (64)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the XERS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 64/100 (C) score, XERS faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($9.39) or 200D SMA ($7.53) invalidates the momentum regime and cuts Target Base ($10.44) toward Bear Floor ($8.14).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $XERS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “XERS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 64%NO 36%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
59.730 Oversold · 70 Hot
ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)
2.11>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE80% OF RANGE
L: $5$10.17H: $11
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (steady margins and healthy balance-sheet cushion).

Factor Grade: B+RQD 16 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C+RQD 27 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

Quant Analyst Panel Split (Battleground) on XERS

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (80)

16.0% ROIC with 42.0% gross margin and 1.46% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (60)

Altman-Z 2.11 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (60)

27/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like XERS
  • ✓Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
Bear Case: What Could Go Wrong
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (XERS Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
XERS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +60.41%▲ ASCENDING CHANNEL
2026-11-03O $10.75H $10.75L $10.17C $10.17VOL 1.55M
RES: $12.31SUP: $8.25SMA50: $9.39SMA200: $7.53
$11.81$10.19$8.56$6.93$5.31RES $12.31SUP $8.25$10.172026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XERS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XERS Butterfly Map → + Track XERS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
48.0%/yr Implied 5Y Growth

vs. +43.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on XERS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XERS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for XERS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XERS)

Health Care Rank #127 of 1015 ⚔️ SLS vs XERS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XERS vs. SLS, SRPT, BRVE, TRVI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Xeris Biopharma Holdings Inc. (XERS) ranks #127 by composite RQD confidence (64/100, grade C) and #259 by equity capitalization ($1.95B). Within this direct 5-issuer industry benchmark cohort, XERS leads on earnings valuation at N/A trailing P/E, while XERS leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. XERS currently leads its immediate peer cohort in composite quantitative strength at 64/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
XERS ACTIVE
Xeris Biopharma Holdings Inc.
C 64/100 — — 16.0% -5.04% $1.95B Benchmark Subject
SLS
SELLAS Life Sciences Group Inc.
D- 38/100 — — -21.8% -11.67% $1.95B /sls-vs-xers →
SRPT
Sarepta Therapeutics Inc.
E 27/100 — 96.0% -35.0% -1.61% $1.97B /srpt-vs-xers →
BRVE
Braveheart Bio Inc.
D 46/100 — — — -2.18% $1.94B /brve-vs-xers →
TRVI
Trevi Therapeutics Inc.
E 30/100 — — -23.7% +0.52% $1.93B /trvi-vs-xers →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001867096 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Xeris Biopharma Holdings Inc. (XERS) reported GAAP revenue of $291.8M (+43.7% vs. FY2024 revenue of $203.1M , and +78.0% cumulative change since FY2023) , GAAP net income of $554.0K, operating cash flow of $28.6M, and free cash flow of $28.6M (+177.4% YoY). On the balance sheet, XERS closed FY2025 with $383.5M in total assets against $220.3M in total debt (Altman Z-Score: 2.11, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $291.8M $554.0K $28.6M $28.6M $383.5M $220.3M
FY2024 (FY) 2024-12-31 $203.1M -$54.8M -$37.0M -$37.0M $323.1M $217.0M
FY2023 (FY) 2023-12-31 $163.9M -$62.3M -$47.0M -$47.0M — —

3. XERS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XERS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Xeris Biopharma Holdings Inc. (NASDAQ: XERS) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $10.17 (-5.04% 1D, market cap $1.95B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, XERS ranks #127 in composite RQD confidence.

How does XERS compare to SLS and SRPT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XERS carries a Roarable C (64/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 16.0%. By comparison, SLS (SELLAS Life Sciences Group Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -21.8%, cap $1.95B) and SRPT (Sarepta Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $1.97B). Among the 5-stock peer group, XERS leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XERS?

Per XERS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001867096), Xeris Biopharma Holdings Inc. generated $291.8M in revenue (+43.7% YoY), $554.0K in net income, and $28.6M in free cash flow against $383.5M in total assets and $220.3M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XERS trading relative to its 50-day, 200-day, and 52-week technical levels?

XERS last traded at $10.17 (-5.04% on volume of 2,309,330 shares), positioning the stock +8.31% above its 50-day simple moving average ($9.39) and +35.06% above its 200-day simple moving average ($7.53). Across its 52-week range of $5.25 to $11.42, XERS sits at the 79.7% percentile with a 14-day RSI of 59.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.7% ($9.29 to $11.05).

Direct Sub-Reports: XERS RQD Cockpit XERS 12M Forecast XERS Earnings & Move XERS Dividends & DRIP XERS Insiders & 13F XERS Whale Options XERS Profit Sankey XERS News & Why
ROARABLE RATING BRIEF • RQD 64/100 (C) ✓ SEC XBRL & RQD VERIFIED

XERS — Xeris Biopharma Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Xeris Biopharma Holdings Inc. (XERS) earns a live Roarable RQD composite score of 64/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $10.17 (-5.04% 1D, market capitalization $1.95B).

  • Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of 16.0%, gross margin of —, operating margin of 8.5%, and free cash flow yield of 1.46%.
  • Whale 13F & Options Flow (16/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (12/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.11, Piotroski F-Score of 7/9, and Debt/Equity of 8.50x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Xeris Biopharma Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry,. — The profile records a market capitalization of $2.0B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Xeris Biopharma Holdings Inc. (XERS) reported $291.8M in annual revenue (up from $203.1M in FY2024, +43.7% YoY) and $554.0K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($163.9M revenue, -$62.3M net income) through FY2025, XERS scaled operating cash flow to $28.6M and free cash flow to $28.6M, backed by $383.5M in total assets against $220.3M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C • RQD 64/100): Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $5.25 – $11.42 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh current valuation and 83.1x EV/EBITDA against 8.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers, downstream customers, and sector correlations for XERS are — Investors should note that the absence of mapped links means second-order ripple effects cannot be assessed from this dataset.

  • Key Question #1: Can XERS sustain or expand its 8.5% operating margin and 16.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $291.8M and free cash flow of $28.6M, how will capital allocation balance growth reinvestment against $220.3M in total debt?
  • Key Question #3: How sensitive is XERS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

XERS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Xeris Biopharma Holdings Inc. (XERS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to XERS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

XERS Bull vs. Bear Conversation Board — What's Your Call at $10.17?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON XERS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on XERS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $12.42 (+16.0%)
📌 Pinned Debate

Revenue grew from $163.9M in FY 2023 to $291.8M in FY 2025 while operating income turned to $24.9M, with ROIC at 16% and a 16/20 Fundam

Picked up a starter position in XERS in my $100K Virtual Cash book at $10.71. Revenue grew from $163.9M in FY 2023 to $291.8M in FY 2025 while operating income turned to $24.9M, with ROIC at 16% and a 16/20 Fundamental Cash Engine score.. Trading inside a $5.25–$11.42 52-week range with 1.46% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

ArenaChamp_24 🐂 BULL

@DeltaGamma_99 Agree on the RQD 64/100 quality, though with 1.0 beta I'm scaling in with half-size at $10.71 and keeping dry powder in case we test $9.96.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $9.00 (-16.0%)
Spot @ $10.71

EV/EBITDA of 83.1 and an FCF yield of 1.46% leave the valuation demanding relative to current cash generation, with debt of $220.3M exc

Careful chasing XERS at $10.71. EV/EBITDA of 83.1 and an FCF yield of 1.46% leave the valuation demanding relative to current cash generation, with debt of $220.3M exceeding cash of $111.0M.. Gross margin is 0.0%, but operating margin is 8.5%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $9.00 on multiple compression.

LIVE TAPE